Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jun 30, 2026
Reporting period
Not applicable
Filed with the SEC
Jul 2, 2026
OfficerOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001159036-26-000096
Filed / recorded
Jul 2, 2026, 8:45 PM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
HALOZYME THERAPEUTICS, INC.
Issuer CIK
1159036
Ticker
HALO
Reporting person
David A Ramsay
Relationship
Officer
Officer title
EVP, PRESIDENT, DRUG DELIVERY
Security
Restricted Stock Units
Table
Derivative (Table II)
Transaction date
Jun 30, 2026
Transaction code
M
Shares / units
10,000
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Direct
Amendment
No
Footnotes from the filing
This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date.